Short answer
ImmunityBio, Inc. (IBRX) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). UAE Emirates Drug Establishment marketing authorization for ANKTIVA across two indications.
ImmunityBio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- UAE Emirates Drug Establishment marketing authorization for ANKTIVA across two indications
- Regulatory clearance expands ANKTIVA’s commercial reach into the UAE
- Press release dated July 29, 2026 provides the indication and authorization details
Item EX-99.1 · Exhibit EX-99.1
- UAE marketing authorization expands ANKTIVA’s footprint to 34 countries across NMIBC and metastatic NSCLC
- First global NMIBC approval spanning CIS with or without papillary tumors and papillary-only disease
- NMIBC data: 71% complete response in 100 CIS patients; 12-month papillary disease-free survival 58.2%
- NSCLC authorization targets checkpoint-refractory disease; median overall survival 14.6 months in 79 patients
- Commercial upside depends on UAE pricing, reimbursement, launch execution, BCG supply, and Modern Pharmaceutical partnership
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ImmunityBio, Inc. 8-K filings
Get the next IBRX 8-K as it lands
Follow IBRX for push alerts, or ask the research agent what this filing means.